A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 2/3 Recruiting
660 enrolled
MagnetisMM-6
Phase 3 Recruiting
1,116 enrolled
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
MajesTEC-7
Phase 3 Recruiting
1,590 enrolled
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1 Recruiting
140 enrolled
Pan Tumor Rollover Study
Phase 2 Recruiting
1,500 enrolled
MAGNETISMM-5
Phase 3 Recruiting
944 enrolled
iMMagine-3
Phase 3 Recruiting
450 enrolled
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 Recruiting
358 enrolled
DURGA-4
Phase 3 Recruiting
508 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1 Recruiting
317 enrolled
DREAMM-10
Phase 3 Recruiting
520 enrolled
STOMP
Phase 1/2 Recruiting
300 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 2 Recruiting
160 enrolled
FUMANBA-03
Phase 3 Recruiting
240 enrolled
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Phase 1/2 Recruiting
128 enrolled
DARVIVA
Phase 3 Recruiting
252 enrolled